Relevance of Receptor for Advanced Glycation end Products (RAGE) in Murine Antibody-Mediated Autoimmune Diseases

It is incompletely understood how self-antigens become targets of humoral immunity in antibody-mediated autoimmune diseases. In this context, alarmins are discussed as an important level of regulation. Alarmins are recognized by various receptors, such as receptor for advanced glycation end products (RAGE). As RAGE is upregulated under inflammatory conditions, strongly binds nucleic acids and mediates pro-inflammatory responses upon alarmin recognition, our aim was to examine its contribution to immune complex-mediated autoimmune diseases. This question was addressed employing RAGE−/− animals in murine models of pristane-induced lupus, collagen-induced, and serum-transfer arthritis. Autoantibodies were assessed by enzyme-linked immunosorbent assay, renal disease by quantification of proteinuria and histology, arthritis by scoring joint inflammation. The associated immune status was determined by flow cytometry. In both disease entities, we detected tendentiously decreased autoantibody levels in RAGE−/− mice, however no differences in clinical outcome. In accordance with autoantibody levels, a subgroup of the RAGE−/− animals showed a decrease in plasma cells, and germinal center B cells and an increase in follicular B cells. Based on our results, we suggest that RAGE deficiency alone does not significantly affect antibody-mediated autoimmunity. RAGE may rather exert its effects along with other receptors linking environmental factors to auto-reactive immune responses.

[1]  A. Rojas,et al.  Inhibition of RAGE Axis Signaling: A Pharmacological Challenge. , 2019, Current drug targets.

[2]  G. Melacini,et al.  Direct binding and internalization of diverse extracellular nucleic acid species through the collagenous domain of class A scavenger receptors , 2018, Immunology and cell biology.

[3]  Jong Seong Roh,et al.  Damage-Associated Molecular Patterns in Inflammatory Diseases , 2018, Immune network.

[4]  M. Lippman,et al.  Targeting RAGE Signaling in Inflammatory Disease. , 2018, Annual review of medicine.

[5]  T. Huizinga,et al.  The role of autoantibodies in the pathophysiology of rheumatoid arthritis , 2017, Seminars in Immunopathology.

[6]  R. Pullerits,et al.  RAGE Deficiency Impairs Bacterial Clearance in Murine Staphylococcal Sepsis, but Has No Significant Impact on Staphylococcal Septic Arthritis , 2016, PloS one.

[7]  E. Wouters,et al.  Advanced glycation end products and their receptor in age-related, non-communicable chronic inflammatory diseases; Overview of clinical evidence and potential contributions to disease. , 2016, The international journal of biochemistry & cell biology.

[8]  C. Mackay,et al.  Avenues to autoimmune arthritis triggered by diverse remote inflammatory challenges. , 2016, Journal of autoimmunity.

[9]  C. Mackay,et al.  The Role of Follicular Helper T Cell Molecules and Environmental Influences in Autoantibody Production and Progression to Inflammatory Arthritis in Mice , 2016, Arthritis & rheumatology.

[10]  M. Andrassy,et al.  Critical role of RAGE and HMGB1 in inflammatory heart disease , 2015, Proceedings of the National Academy of Sciences.

[11]  K. Pietrosimone,et al.  Collagen-Induced Arthritis: A model for Murine Autoimmune Arthritis. , 2015, Bio-protocol.

[12]  B. Diamond,et al.  Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. , 2015, The Journal of clinical investigation.

[13]  P. Rieu,et al.  Deletion of Receptor for Advanced Glycation End Products Exacerbates Lymphoproliferative Syndrome and Lupus Nephritis in B6-MRL Fas lpr/j Mice , 2015, The Journal of Immunology.

[14]  Xiaoyang Wang,et al.  Antibiotic‐Killed Staphylococcus aureus Induces Destructive Arthritis in Mice , 2015, Arthritis & rheumatology.

[15]  C. Mackay,et al.  Inflammation and Lymphopenia Trigger Autoimmunity by Suppression of IL-2–Controlled Regulatory T Cell and Increase of IL-21–Mediated Effector T Cell Expansion , 2014, The Journal of Immunology.

[16]  Q. Lu,et al.  TLR2 and TLR4 in Autoimmune Diseases: a Comprehensive Review , 2014, Clinical Reviews in Allergy & Immunology.

[17]  D. Pisetsky,et al.  The Role of HMGB1 in the Pathogenesis of Inflammatory and Autoimmune Diseases , 2014, Molecular medicine.

[18]  E. Latz,et al.  RAGE is a nucleic acid receptor that promotes inflammatory responses to DNA , 2013, The Journal of experimental medicine.

[19]  K. Miyamoto,et al.  Bone-Targeting Endogenous Secretory Receptor for Advanced Glycation End Products Rescues Rheumatoid Arthritis , 2013, Molecular Medicine.

[20]  G. Fritz,et al.  RAGE regulation and signaling in inflammation and beyond , 2013, Journal of leukocyte biology.

[21]  Sungha Park,et al.  Soluble receptor for advanced glycation end products alleviates nephritis in (NZB/NZW)F1 mice. , 2013, Arthritis and rheumatism.

[22]  C. Daniel,et al.  Toll-like receptor 2 is required for autoantibody production and development of renal disease in pristane-induced lupus. , 2013, Arthritis and rheumatism.

[23]  M. Kirchner,et al.  Surface expression and genotypes of Toll-like receptors 2 and 4 in patients with juvenile idiopathic arthritis and systemic lupus erythematosus , 2013, Pediatric Rheumatology.

[24]  A. Rojas,et al.  The receptor for advanced glycation end-products: a complex signaling scenario for a promiscuous receptor. , 2013, Cellular signalling.

[25]  J. Aloor,et al.  CD11b/CD18 (Mac-1) Is a Novel Surface Receptor for Extracellular Double-Stranded RNA To Mediate Cellular Inflammatory Responses , 2013, The Journal of Immunology.

[26]  M. Nussenzweig,et al.  DEC-205 is a cell surface receptor for CpG oligonucleotides , 2012, Proceedings of the National Academy of Sciences.

[27]  Shih-Chang Lin,et al.  Altered IL-10 and TNF-α production in peripheral blood mononuclear cells of systemic lupus erythematosus patients after Toll-like receptor 2, 4, or 9 activation , 2012, Clinical and Experimental Medicine.

[28]  Y. Jiao,et al.  The Plasma Level of Soluble Receptor for Advanced Glycation End Products is Decreased in Patients with Systemic Lupus Erythematosus , 2012, Scandinavian journal of immunology.

[29]  A. Papavassiliou,et al.  Crosstalk between advanced glycation and endoplasmic reticulum stress: emerging therapeutic targeting for metabolic diseases. , 2012, The Journal of clinical endocrinology and metabolism.

[30]  M. Bijl,et al.  Receptor for advanced glycation end products (RAGE) polymorphisms are associated with systemic lupus erythematosus and disease severity in lupus nephritis , 2012, Lupus.

[31]  U. Andersson,et al.  HMGB1: A multifunctional alarmin driving autoimmune and inflammatory disease , 2012, Nature Reviews Rheumatology.

[32]  Georg Schett,et al.  The pathogenesis of rheumatoid arthritis. , 2011, The New England journal of medicine.

[33]  R. Ramasamy,et al.  Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications , 2011, Annals of the New York Academy of Sciences.

[34]  A. Myles,et al.  Soluble Receptor for Advanced Glycation Endproducts Is Decreased in Patients with Juvenile Idiopathic Arthritis (ERA Category) and Inversely Correlates with Disease Activity and S100A12 Levels , 2011, The Journal of Rheumatology.

[35]  M. Rossol,et al.  Toll-Like Receptor 4 Is Involved in Inflammatory and Joint Destructive Pathways in Collagen-Induced Arthritis in DBA1J Mice , 2011, PloS one.

[36]  W. B. van den Berg,et al.  S100A8 enhances osteoclastic bone resorption in vitro through activation of Toll-like receptor 4: implications for bone destruction in murine antigen-induced arthritis. , 2011, Arthritis and rheumatism.

[37]  K. Tracey,et al.  HMGB1 is a therapeutic target for sterile inflammation and infection. , 2011, Annual review of immunology.

[38]  L. Morel,et al.  Murine Models of Systemic Lupus Erythematosus , 2011, Journal of biomedicine & biotechnology.

[39]  N. Gretz,et al.  The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis. , 2010, The Journal of clinical investigation.

[40]  V. D’Agati,et al.  RAGE and the pathogenesis of chronic kidney disease , 2010, Nature Reviews Nephrology.

[41]  W. Nacken,et al.  The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells , 2010, Nature Medicine.

[42]  S. Akira,et al.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors , 2010, Nature Immunology.

[43]  A. Coyle,et al.  HMGB1 and RAGE in inflammation and cancer. , 2010, Annual review of immunology.

[44]  D. Teachey,et al.  Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS) , 2010, British journal of haematology.

[45]  C. Arnoult,et al.  Critical Role of TLR2 and TLR4 in Autoantibody Production and Glomerulonephritis in lpr Mutation-Induced Mouse Lupus1 , 2009, The Journal of Immunology.

[46]  C. Heizmann,et al.  Binding of S100 proteins to RAGE: an update. , 2009, Biochimica et biophysica acta.

[47]  C. Langefeld,et al.  Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies , 2009, Nature Reviews Genetics.

[48]  A. Schmidt,et al.  RAGE: a novel biological and genetic marker for vascular disease. , 2009, Clinical science.

[49]  M. Brown,et al.  Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis , 2009, Arthritis research & therapy.

[50]  M. Bianchi,et al.  Induction of inflammatory and immune responses by HMGB1–nucleosome complexes: implications for the pathogenesis of SLE , 2008, The Journal of experimental medicine.

[51]  P. Tak,et al.  Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: toll-like receptor expression in early and longstanding arthritis. , 2008, Arthritis and rheumatism.

[52]  P. Saftig,et al.  A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane‐bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10) , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[53]  M. Kowalski,et al.  Increased Responsiveness to Toll-Like Receptor 4 Stimulation in Peripheral Blood Mononuclear Cells from Patients with Recent Onset Rheumatoid Arthritis , 2008, Mediators of inflammation.

[54]  A. Komatsuda,et al.  Up‐regulated expression of Toll‐like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus , 2008, Clinical and experimental immunology.

[55]  N. Kaminski,et al.  A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. , 2008, The American journal of pathology.

[56]  L. Joosten,et al.  Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. , 2008, The Journal of clinical investigation.

[57]  D. Stern,et al.  RAGE in inflammation: a new therapeutic target? , 2006, Current opinion in investigational drugs.

[58]  Li Lin RAGE on the Toll Road? , 2006, Cellular & molecular immunology.

[59]  A. Smit,et al.  Accumulation of advanced glycation endproducts in patients with systemic lupus erythematosus. , 2006, Rheumatology.

[60]  C. Falcone,et al.  Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. , 2006, Current medicinal chemistry.

[61]  I. Matsumoto,et al.  Critical role of M. tuberculosis for dendritic cell maturation to induce collagen‐induced arthritis in H‐2b background of C57BL/6 mice , 2006, Immunology.

[62]  D. Stern,et al.  Understanding RAGE, the receptor for advanced glycation end products , 2005, Journal of Molecular Medicine.

[63]  Andrej Tarkowski,et al.  Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control , 2005, Arthritis research & therapy.

[64]  L. Joosten,et al.  Expression of toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-gamma. , 2004, Arthritis and rheumatism.

[65]  Shizuo Akira,et al.  Toll-like receptor signalling , 2004, Nature Reviews Immunology.

[66]  E. Schleicher,et al.  Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. , 2004, The Journal of clinical investigation.

[67]  T. Misteli,et al.  Release of chromatin protein HMGB1 by necrotic cells triggers inflammation , 2002, Nature.

[68]  R. de Caterina,et al.  Advanced Glycation End Products Activate Endothelium Through Signal-Transduction Receptor RAGE: A Mechanism for Amplification of Inflammatory Responses , 2002, Circulation.

[69]  A. Schmidt,et al.  The biology of the receptor for advanced glycation end products and its ligands. , 2000, Biochimica et biophysica acta.

[70]  V. D’Agati,et al.  Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. , 2000, Journal of the American Society of Nephrology : JASN.

[71]  T. Kislinger,et al.  N ε-(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene Expression* , 1999, The Journal of Biological Chemistry.

[72]  M. Neurath,et al.  RAGE Mediates a Novel Proinflammatory Axis A Central Cell Surface Receptor for S100/Calgranulin Polypeptides , 1999, Cell.

[73]  K. Rajewsky,et al.  From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. , 1999, Immunity.

[74]  A. Schmidt,et al.  Activation of the Receptor for Advanced Glycation End Products Triggers a p21 ras -dependent Mitogen-activated Protein Kinase Pathway Regulated by Oxidant Stress* , 1997, The Journal of Biological Chemistry.

[75]  M. Matsumoto,et al.  Rage: A Novel Cellular Receptor for Advanced Glycation End Products , 1996, Diabetes.

[76]  D. Isenberg,et al.  Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. , 1995, Kidney international.

[77]  R. Eisenberg,et al.  Apoptosis abnormalities of splenic lymphocytes in autoimmune lpr and gld mice. , 1995, Journal of immunology.

[78]  M. Smith,et al.  Advanced Maillard reaction end products are associated with Alzheimer disease pathology , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[79]  Y. Zou,et al.  Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. , 1993, The American journal of pathology.

[80]  P. Schur,et al.  Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. , 1966, The Journal of clinical investigation.

[81]  D. Cholujová,et al.  Increased production of IL-6 and IL-17 in lipopolysaccharide-stimulated peripheral mononuclears from patients with rheumatoid arthritis. , 2013, General physiology and biophysics.

[82]  이상원,et al.  Soluble Receptor for Advanced Glycation End Products Alleviates Nephritis in (NZB/NZW)F1 Mice , 2013 .

[83]  J. Winfield,et al.  Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus. Association of high avidity antinative DNA antibody with glomerulonephritis. , 1977, The Journal of clinical investigation.